CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 233 filers reported holding CLOVIS ONCOLOGY INC in Q1 2018. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $89,000 | -62.8% | 49,400 | -58.3% | 0.00% | -100.0% |
Q1 2022 | $239,000 | -60.8% | 118,500 | -47.3% | 0.00% | -50.0% |
Q4 2021 | $609,000 | +107.1% | 224,900 | +241.3% | 0.00% | +100.0% |
Q3 2021 | $294,000 | +83.8% | 65,900 | +162.5% | 0.00% | 0.0% |
Q1 2020 | $160,000 | -94.5% | 25,100 | -96.6% | 0.00% | -85.7% |
Q3 2019 | $2,923,000 | +243.1% | 743,706 | +1197.8% | 0.01% | +250.0% |
Q2 2019 | $852,000 | +54.6% | 57,306 | +158.1% | 0.00% | +100.0% |
Q1 2019 | $551,000 | -83.3% | 22,200 | -54.1% | 0.00% | -88.9% |
Q4 2017 | $3,291,000 | +648.0% | 48,400 | +929.8% | 0.01% | +800.0% |
Q2 2017 | $440,000 | -50.3% | 4,700 | -66.2% | 0.00% | -66.7% |
Q1 2017 | $885,000 | -8.4% | 13,900 | -49.6% | 0.00% | -50.0% |
Q4 2015 | $966,000 | +0.9% | 27,601 | +165.2% | 0.01% | 0.0% |
Q3 2015 | $957,000 | +80.6% | 10,406 | -18.7% | 0.01% | +50.0% |
Q2 2014 | $530,000 | – | 12,806 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |